Dasiglucagon Treatment for Postprandial Hypoglycemia After Gastric Bypass: A Randomized, Double-Blind, Placebo-Controlled Trial

What Was Tested

Researchers studied Glucagon in this randomized controlled trial publication.

Despite the often debilitating nature of this complication, existing treatment options are limited and often inefficient.

Here, the researchers aimed to evaluate the hypoglycemic hindering potential of dasiglucagon in an outpatient trial.

Who Took Part

The study group was 24 individuals.

PubMed tags the participants as women only.

How the Study Was Run

The researchers set it up as a randomized, double-blind, placebo-controlled and crossover study.

The individuals were allocated by chance, so the Glucagon group and the comparison group should start out alike.

Neither the individuals nor the staff measuring them knew who was on Glucagon, so expectations could not easily colour the readings.

The comparison arm used a placebo, so changes seen with Glucagon could be set against what happens without it.

In the crossover set-up each of the individuals took both Glucagon and the comparison in turn, acting as their own control.

The researchers conducted a randomized, double-blind, placebo-controlled, crossover, proof-of-concept study at the Center for Clinical Metabolic Research at Gentofte Hospital in Denmark.

What Was Measured

Topics PubMed links to this paper include Glucagon, Gastric Bypass, Hypoglycemia and Blood Glucose.

What This Means in Plain Language

The paper is a randomized, double-blind and placebo-controlled study of Glucagon in 24 individuals.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Results are reported in around 4 sentences of the abstract; we leave them to the paper itself rather than summarise them.

The publication is from 2023 (Diabetes care), a journal based in United States.

More context: the Glucagon compound page, all human trials.